Marla Persky - 03 Jun 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Director
Issuer ticker: XERS
Reported as of: 03 Jun 2026
Net transaction value: -$91,433
SEC form: 4
Accepted by SEC: 05 Jun 2026, 18:29:31 UTC
Prior SEC filing: 12 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, Attorney-in-Fact

Key filing fact

Marla Persky filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 05 Jun 2026.

Key facts

This page summarizes Marla Persky's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 18:29.

Change

Previous filing in this sequence was filed on 12 Sep 2025.
Current net transaction value: -$91,433.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001270354 Primary reporting owner

PERSKY MARLA

Relationship: Director
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht, Attorney-in-Fact
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Sale

Transaction value: $91,433
Shares: -15,500
Change %: -11%
Price: $5.90
Shares after: 126,500
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F1, F2

XERS transaction

Common Stock

Award

Transaction value
Shares: +24,193
Change %: +19%
Price: $0.000000^*
Shares after: 150,693
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F3

XERS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,370
Date: 03 Jun 2026
Ownership: By: Marla Susan Persky Revocable Trust u/a dated 9/23/2000
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XERS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +32,996
Change %
Price: $6.15^*
Shares after: 32,996
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,996
Exercise price: $6.15
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.810 to $5.960, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Footnote F4

The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F5

These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.